-
Trends in COVID-19 hospital outcomes in England before and after vaccine introduction, a cohort study
Authors:
Peter Kirwan,
Andre Charlett,
Paul Birrell,
Suzanne Elgohari,
Russell Hope,
Sema Mandal,
Daniela De Angelis,
Anne Presanis
Abstract:
Widespread vaccination campaigns have changed the landscape for COVID-19, vastly altering symptoms and reducing morbidity and mortality. We estimate trends in mortality by month of admission and vaccination status among those hospitalised with COVID-19 in England between March 2020 to September 2021, controlling for demographic factors and hospital load.
Among 259,727 hospitalised COVID-19 cases…
▽ More
Widespread vaccination campaigns have changed the landscape for COVID-19, vastly altering symptoms and reducing morbidity and mortality. We estimate trends in mortality by month of admission and vaccination status among those hospitalised with COVID-19 in England between March 2020 to September 2021, controlling for demographic factors and hospital load.
Among 259,727 hospitalised COVID-19 cases, 51,948 (20.0%) experienced mortality in hospital. Hospitalised fatality risk ranged from 40.3% (95% confidence interval 39.4-41.3%) in March 2020 to 8.1% (7.2-9.0%) in June 2021. Older individuals and those with multiple co-morbidities were more likely to die or else experienced longer stays prior to discharge. Compared to unvaccinated people, the hazard of hospitalised mortality was 0.71 (0.67-0.77) with a first vaccine dose, and 0.56 (0.52-0.61) with a second vaccine dose. Compared to hospital load at 0-20% of the busiest week, the hazard of hospitalised mortality during periods of peak load (90-100%), was 1.23 (1.12-1.34).
The prognosis for people hospitalised with COVID-19 in England has varied substantially throughout the pandemic and according to case-mix, vaccination, and hospital load. Our estimates provide an indication for demands on hospital resources, and the relationship between hospital burden and outcomes.
△ Less
Submitted 3 August, 2022; v1 submitted 20 December, 2021;
originally announced December 2021.
-
Evaluating the impact of local tracing partnerships on the performance of contact tracing for COVID-19 in England
Authors:
Pantelis Samartsidis,
Shaun R. Seaman,
Abbie Harrison,
Angelos Alexopoulos,
Gareth J. Hughes,
Christopher Rawlinson,
Charlotte Anderson,
Andre Charlett,
Isabel Oliver,
Daniela De Angelis
Abstract:
Assessing the impact of an intervention using time-series observational data on multiple units and outcomes is a frequent problem in many fields of scientific research. In this paper, we present a novel method to estimate intervention effects in such a setting by generalising existing approaches based on the factor analysis model and develo** a Bayesian algorithm for inference. Our method is one…
▽ More
Assessing the impact of an intervention using time-series observational data on multiple units and outcomes is a frequent problem in many fields of scientific research. In this paper, we present a novel method to estimate intervention effects in such a setting by generalising existing approaches based on the factor analysis model and develo** a Bayesian algorithm for inference. Our method is one of the few that can simultaneously: deal with outcomes of mixed type (continuous, binomial, count); increase efficiency in the estimates of the causal effects by jointly modelling multiple outcomes affected by the intervention; easily provide uncertainty quantification for all causal estimands of interest. We use the proposed approach to evaluate the impact that local tracing partnerships (LTP) had on the effectiveness of England's Test and Trace (TT) programme for COVID-19. Our analyses suggest that, overall, LTPs had a small positive impact on TT. However, there is considerable heterogeneity in the estimates of the causal effects over units and time.
△ Less
Submitted 5 October, 2021;
originally announced October 2021.
-
Hospitalisation risk for COVID-19 patients infected with SARS-CoV-2 variant B.1.1.7: cohort analysis
Authors:
Tommy Nyberg,
Katherine A. Twohig,
Ross J. Harris,
Shaun R. Seaman,
Joe Flannagan,
Hester Allen,
Andre Charlett,
Daniela De Angelis,
Gavin Dabrera,
Anne M. Presanis
Abstract:
Objective: To evaluate the relationship between coronavirus disease 2019 (COVID-19) diagnosis with SARS-CoV-2 variant B.1.1.7 (also known as Variant of Concern 202012/01) and the risk of hospitalisation compared to diagnosis with wildtype SARS-CoV-2 variants.
Design: Retrospective cohort, analysed using stratified Cox regression.
Setting: Community-based SARS-CoV-2 testing in England, individu…
▽ More
Objective: To evaluate the relationship between coronavirus disease 2019 (COVID-19) diagnosis with SARS-CoV-2 variant B.1.1.7 (also known as Variant of Concern 202012/01) and the risk of hospitalisation compared to diagnosis with wildtype SARS-CoV-2 variants.
Design: Retrospective cohort, analysed using stratified Cox regression.
Setting: Community-based SARS-CoV-2 testing in England, individually linked with hospitalisation data.
Participants: 839,278 laboratory-confirmed COVID-19 patients, of whom 36,233 had been hospitalised within 14 days, tested between 23rd November 2020 and 31st January 2021 and analysed at a laboratory with an available TaqPath assay that enables assessment of S-gene target failure (SGTF). SGTF is a proxy test for the B.1.1.7 variant. Patient data were stratified by age, sex, ethnicity, deprivation, region of residence, and date of positive test.
Main outcome measures: Hospitalisation between 1 and 14 days after the first positive SARS-CoV-2 test.
Results: 27,710 of 592,409 SGTF patients (4.7%) and 8,523 of 246,869 non-SGTF patients (3.5%) had been hospitalised within 1-14 days. The stratum-adjusted hazard ratio (HR) of hospitalisation was 1.52 (95% confidence interval [CI] 1.47 to 1.57) for COVID-19 patients infected with SGTF variants, compared to those infected with non-SGTF variants. The effect was modified by age (P<0.001), with HRs of 0.93-1.21 for SGTF compared to non-SGTF patients below age 20 years, 1.29 in those aged 20-29, and 1.45-1.65 in age groups 30 years or older.
Conclusions: The results suggest that the risk of hospitalisation is higher for individuals infected with the B.1.1.7 variant compared to wildtype SARS-CoV-2, likely reflecting a more severe disease. The higher severity may be specific to adults above the age of 30.
△ Less
Submitted 29 May, 2021; v1 submitted 12 April, 2021;
originally announced April 2021.
